The Indolent B-Cell Lymphomas

  • Peter McLaughlin
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 131)

Abstract

The indolent B-cell lymphomas account for about one third of all lymphomas in the Western world. The follicular lymphomas are the largest and most easily recognized category of indolent lymphoma, representing about one quarter of lymphomas in the Western world.1, 2, 3 The incidence of follicular lymphoma is markedly lower in Asia than in the West, for unclear reasons.4 Other well-defined indolent lymphomas (and their approximate percentage incidence) are: small lymphocytic lymphoma (6%); nodal marginal zone B-cell lymphoma (1–2%); extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, or MALT (5–7%); splenic marginal zone B-cell lymphoma, and the variant splenic lymphoma with villous lymphocytes (< 1%); and lymphoplasmacytic lymphoma (1%).

Keywords

Clin Oncol Chronic Lymphocytic Leukemia Follicular Lymphoma Malt Lymphoma Marginal Zone Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

9. References

  1. 1.
    Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3853–3849Google Scholar
  2. 2.
    Nathwani BN, Harris NL, Weisenburger D, Isaacson PG, Piris MA, Berger F, Müller-Hermelink HK, Swerdlow SH. Follicular Lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC 2001: Pages 162–167Google Scholar
  3. 3.
    Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–95PubMedGoogle Scholar
  4. 4.
    Biagi JJ, Seymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 2002; 99: 4265–4275PubMedCrossRefGoogle Scholar
  5. 5.
    Coiffier B, Thieblemont C., Felman P, et al: Indolent nonfollicular lymphomas: characteristics, treatment, and outcome. Semin Hematol 1999; 36: 198–208PubMedGoogle Scholar
  6. 6.
    Eck M, Schmaußer B, Greiner A, and Müller-Hermelink K: Helicobacter pylori in gastric mucosa-associated lymphoid tissue type lymphoma. In: Fischback W, ed., Gastrointestinal Lymphoma: Future Perspectives. Springer-Verlag Berlin-Heidelberg 2000 (Recent Results in Cancer Research, Vol. 156): pages 9–18Google Scholar
  7. 7.
    Wotherspoon AC, Doglioni C, Diss TC, et al: Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575–577PubMedCrossRefGoogle Scholar
  8. 8.
    Hofbauer GF, Kessler B, Kempf W, et al: Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment. Dermatology 2001; 203: 168–170PubMedCrossRefGoogle Scholar
  9. 9.
    Ferreri AJM, Guidoboni M, Ponzoni M, et al: Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96: 586–594PubMedCrossRefGoogle Scholar
  10. 10.
    Auer IA, Gascoyne RD, Connors JM, et al: t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncol 1997; 8: 979–985PubMedCrossRefGoogle Scholar
  11. 11.
    Willis TG, Jadayel DM, Du MQ, et al: Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96: 35–45PubMedCrossRefGoogle Scholar
  12. 12.
    Jaffe ES: Follicular lymphoma: Possibility that they are benign tumors of the lymphoid system. JNCI 1983; 70: 401–403PubMedGoogle Scholar
  13. 13.
    Dave S, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-Infiltrating immune cells. N Engl J Med 2004; 351: 2159–2169PubMedCrossRefGoogle Scholar
  14. 14.
    Lossos IS, Alizadeh AA, Diehn M, et al: Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 2002; 99: 8886–8891PubMedCrossRefGoogle Scholar
  15. 15.
    Elinitoba-Johnson KS, Jenson SD, Abbott RT, et al: Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogenactivated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003; 100: 7259–7264CrossRefGoogle Scholar
  16. 16.
    Glas AM, Kersten, MJ, Delahaye LJMJ, et al: Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2002; 105: 301–307CrossRefGoogle Scholar
  17. 17.
    Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2005; 346: 1937–1947CrossRefGoogle Scholar
  18. 18.
    Korsmeyer S. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992;80: 879–886PubMedGoogle Scholar
  19. 19.
    Albinger-Hegyi A, Hochreutener B, Abdou M-T, et al: High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas. Improved polymerase chain reaction protocols for their detection. Am J Pathol 2002; 160: 823–832PubMedGoogle Scholar
  20. 20.
    Liu NS, Medeiros LJ, Cabanillas F, et al: Prognostic relevance of t(14;18) status in follicular lymphoma. Proc ASCO 2003; 22: 2219 (abstr)Google Scholar
  21. 21.
    Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al: Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 1999; 93: 3081–3087PubMedGoogle Scholar
  22. 22.
    Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al: Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003; 101: 1145–1154CrossRefGoogle Scholar
  23. 23.
    Lee MS, Chang KS, Cabanillas F, et al: Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 1987; 237: 175–178PubMedCrossRefGoogle Scholar
  24. 24.
    Gribben JG, Nuberg D, Barber M, et al: Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800–3807PubMedGoogle Scholar
  25. 25.
    Waters JS, Webb A, Cunningham D, et al: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol 2000; 18: 1812–1823PubMedGoogle Scholar
  26. 26.
    Horning SJ: Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993; 20: 75–80PubMedGoogle Scholar
  27. 27.
    Brice P, Bastion Y, Lepage E, et al: Comparision in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Grope d’Etude des Lymphomes de FAdulte. J Clin Oncol 1997; 15: 1110–1117PubMedGoogle Scholar
  28. 28.
    Ardeshna KM, Smith P, Norton A, et al: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet 2003; 362-: 516–522PubMedCrossRefGoogle Scholar
  29. 29.
    Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988; (2Suppl 2):11–6Google Scholar
  30. 30.
    Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 1984; 311: 1471–1475PubMedCrossRefGoogle Scholar
  31. 31.
    Liu Q, Fayad L, Hagemeister FB, et al: Stage IV indolent lymphoma: 25 years of treatment progress. Blood 2003; 102: 398a (abstr)Google Scholar
  32. 32.
    Van Besien K, Sobocinski KA, Rowlings PA et al: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832–1836PubMedGoogle Scholar
  33. 33.
    Petersen PM Gospodarowicz M, Tsang R, et al: Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. Proc ASCO 2004; 23: 561 (abstr)Google Scholar
  34. 34.
    Hehn ST, Grogan TM, Miller TP: Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 2004; 22: 3046–3052PubMedCrossRefGoogle Scholar
  35. 35.
    Shipp MA, Harrington DP, Anderson JR, et al: The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987–994CrossRefGoogle Scholar
  36. 36.
    Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265PubMedCrossRefGoogle Scholar
  37. 37.
    Lopez-Guillermo A, Montserrat E, Bosch F, et al: Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343–1348PubMedGoogle Scholar
  38. 38.
    Dimoupolous MA, Cabanillas F, Lee JJ, et al: Prognostic role of serum beta 2-microglobulin in Hodgkin’s disease. J Clin Oncol 1993; 11: 1108–1111Google Scholar
  39. 39.
    Swan F, Velasquez WS, Tucker S, et al: A new serologic staging system for large-cell lymphomas based on initial β2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989; 7:1518–1527PubMedGoogle Scholar
  40. 40.
    Litam P, Swan F, Cabanillas F, et al: Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med 1991; 114: 855–860PubMedGoogle Scholar
  41. 41.
    Johnson PWM, Swinbank K, MacLennan S, et al: Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. Ann Oncol 1999; 10: 1349–1354PubMedCrossRefGoogle Scholar
  42. 42.
    Summers KE, Davies AJ, Matthews J, et al: The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction. Br J Haematol 2002; 118: 563–566PubMedCrossRefGoogle Scholar
  43. 43.
    Schiiler F. Hirt C, Dölken G: Chromosomal translocation t(14;18) in healthy individuals. Semin Cancer Biology 2003; 13: 203–209CrossRefGoogle Scholar
  44. 44.
    Price CGA, Meerabux J, Murtagh S, et al: The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma. J Clin Oncol 1991; 9: 1527–1532PubMedGoogle Scholar
  45. 45.
    Colombat P, Garrigue MA, Lamagnere JP, et al: bcl-2 evaluation in patients in long-term complete remission after bone marrow transplantation. J Clin Oncol 1994; 12: 2516 (letter)PubMedGoogle Scholar
  46. 46.
    Johnson PWM, Price CGA, Smith T, et al: Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994; 12: 798–805PubMedGoogle Scholar
  47. 47.
    Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333PubMedGoogle Scholar
  48. 48.
    Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al: The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998; 91: 2955–2960PubMedGoogle Scholar
  49. 49.
    Czuczman MS, Grillo-Lopez AJ, McLaughlin P, et al: Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Annals of Oncology 2001; 12: 109–114PubMedCrossRefGoogle Scholar
  50. 50.
    Rambaldi A, Lazzari M, Manzoni C, et al: Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856–862PubMedCrossRefGoogle Scholar
  51. 51.
    Blum R, Seymour JF, Wirth A, et al: Evaluation of 18-FDG-PET in the staging of patients with indolent non-Hodgkin’s lymphoma. Ann Oncol 2002; 13(suppl 2): 45a (abstr)Google Scholar
  52. 52.
    Friedberg JW, Chengazi V: PET scans in the staging of lymphoma: current status. The Oncologist 2003; 8: 438–447PubMedCrossRefGoogle Scholar
  53. 53.
    Dabaja BS, Ha CS, Wilder RB, Pro B, McLaughlin P, Cabanillas F, Cox JD: Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer J 2003; 9: 321–324PubMedCrossRefGoogle Scholar
  54. 54.
    Paryani SB, Hoppe RT, Cox RS, et al: Analysis of hon-Hodgkin’s lymphomas with nodular and favorable histologies, stages I and II. Cancer 1983; 52: 2300–2307PubMedCrossRefGoogle Scholar
  55. 55.
    Mac Manus MP and Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282–1290PubMedGoogle Scholar
  56. 56.
    McLaughlin P, Fuller LM, Velasquez WS, et al: Stage I-II follicular lymphoma: Treatment results for 76 patients. Cancer 1986; 58:1596–1602PubMedCrossRefGoogle Scholar
  57. 57.
    Seymour JF, Pro B, Fuller LM, et al: Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin’s lymphoma. J Clin Oncol 2003; 21: 2115–2122PubMedCrossRefGoogle Scholar
  58. 58.
    Soybeyran P, Eghbali H, Trojani M, et al: Is there any place for a wait-and-see policy in stage 10 follicular lymphoma? A study of 42 consecutive patients in a single center. Ann Oncol 1996; 7: 713–718Google Scholar
  59. 59.
    Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22: 1454–1459PubMedCrossRefGoogle Scholar
  60. 60.
    Ha CS, Kong JS, McLaughlin P: et al: Stage III follicular lymphoma: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2003; 57: 748–754PubMedCrossRefGoogle Scholar
  61. 61.
    Jacobs JP, Murray KJ, Schultz CJ, et al: Central lymphatic irradiation for stage HI nodular malignant lymphoma: Long-term results. J Clin Oncol 1993; 11: 233–238.PubMedGoogle Scholar
  62. 62.
    McLaughlin P., Fuller LM, Velasquez WS, et al: Stage III follicular lymphoma: Durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 1987; 5: 867–8741PubMedGoogle Scholar
  63. 63.
    Zelenetz AD, Appelbaum FR, Buadi F, et al: The NCCN non-Hodgkin’s lymphoma clinical practice guidelines. Journal of the National Comprehensive Cancer Center Network 2004; 2: 226–336Google Scholar
  64. 64.
    Peterson BA, Petroni GR, Frizzera G, et al: Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the Cancer And Leukemia Group B. J Clin Oncol 2003; 21:5–15PubMedCrossRefGoogle Scholar
  65. 65.
    Rigacci L, Federico M, Martelli M, et al: The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: Retrospective study of the Intergruppo Italiano Linfomi on 761 cases. Leuk & Lymphoma 2003; 44: 1911–1917CrossRefGoogle Scholar
  66. 66.
    Jones SE, Grozea PN, Metz EN, et al: Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer 1983; 51: 1083–1090PubMedCrossRefGoogle Scholar
  67. 67.
    Rohatiner AZS, Gregory W, Peterson B, et al: A meta-analysis of randomized trials evaluating the role of interferon as treatment for follicular lymphoma. Proc ASCO 1998; 17: 4a(abstr)Google Scholar
  68. 68.
    Allen IE, Ross SD, Borden SP, et al: Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin’s lymphoma. J Immunother 2001: 58–65Google Scholar
  69. 69.
    Czuczman M, Weaver R, Alkuzweny, et al: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716PubMedCrossRefGoogle Scholar
  70. 70.
    Redman J, Cabanillas F, Velasquez W, et al: Phase II trial of fludarabine phosphate in lymphoma: an effective new agent for low-grade lymphoma. J Clin Oncol 1998; 10: 790–794Google Scholar
  71. 71.
    Solal-Celigny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1996; 14: 514–519PubMedGoogle Scholar
  72. 72.
    McLaughlin P, Hagemeister FB, Romaguera JE, et al: Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262–1268PubMedGoogle Scholar
  73. 73.
    Zinzani PL, Bendandi M, Magagnoli M, et al: Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin’s lymphoma Ann Oncol 1997; 8: 379–383PubMedCrossRefGoogle Scholar
  74. 74.
    Tsimberidou AM, McLaughlin P, Younes A, et al: Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 2002; 100: 4351–4357PubMedCrossRefGoogle Scholar
  75. 75.
    Zinzani PL, Pulsoni A, Perrotti A, et al: Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654–2661PubMedCrossRefGoogle Scholar
  76. 76.
    Velasquez WS, Lew D, Grogan TM, et al: Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 2003; 21: 1996–2003PubMedCrossRefGoogle Scholar
  77. 77.
    Solal-Celigny P, Lepage E, Brousse N, et al: Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 1998; 16: 2332–2338PubMedGoogle Scholar
  78. 78.
    Verstovsek S, Romaguera JE, Cabanillas F, et al: CHOP-Bleo plus interferon-α for stage IV low grade lymphoma-an update after 13-year follow up: significant improvement in both overall end failure-free survival. Blood 1999; 94(suppl. 1, part 2): 270b(abstr)Google Scholar
  79. 79.
    Fisher RI, Dana BW, LeBlanc M, et al: Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin’s lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 2000; 18: 2010–2016PubMedGoogle Scholar
  80. 80.
    Cole BF, Solal-Celigny P, Gelber RD, et al: Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol 1998; 16: 2339–2344PubMedGoogle Scholar
  81. 81.
    Friedberg JW, Kim H, McCauley M, et al: Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood 2005; 105: 489–495PubMedCrossRefGoogle Scholar
  82. 82.
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833PubMedGoogle Scholar
  83. 83.
    Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997; 90: 2188–2195PubMedGoogle Scholar
  84. 84.
    Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101–106PubMedCrossRefGoogle Scholar
  85. 85.
    Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416–4423PubMedCrossRefGoogle Scholar
  86. 86.
    Hainsworth, JD, Litchy S, Burris HA, et al: rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol 2002; 20: 4261–4267PubMedCrossRefGoogle Scholar
  87. 87.
    Kimby E, Geisler C, Hagberg H, et al: Rituximab as single agent and in combination with interferon-α-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas. A randomized phase II study. Ann Oncol 2002; 13(Suppl 2): 85 (abstr)Google Scholar
  88. 88.
    Alas S, Emmanouilides C, Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Can Res 2004; 7: 709–723Google Scholar
  89. 89.
    Di Gaetano N, Xiao Y, Erba R, Bassan R, Rambaldi A, Golay J, Introna M: Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800–809PubMedCrossRefGoogle Scholar
  90. 90.
    McLaughlin P, Rodriguez MA, Hagemeister FB, et al: Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab monoclonal antibody therapy, with interferon maintenance. Proc ASCO 2003; 22: 564 (abstr)Google Scholar
  91. 91.
    Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood online October 2004Google Scholar
  92. 92.
    Hiddemann W, Dreyling MH, Forstpointner R, et al: Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2003; 102: 104a (abstr)Google Scholar
  93. 93.
    Hochster HS, Weller E, Ryan T, et al: Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Proc ASCO 2004; 23:556 (abstr)Google Scholar
  94. 94.
    Kaminiski MS, Tuck M, Regan, et al: High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine 1–131 tositumomab (Bexxar®). Blood 2002; 100(suppl): 356a (abstr) — N Engl J Med 2005, in pressGoogle Scholar
  95. 95.
    Press OW, Unger JM, Braziel RM, et al: A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003; 102: 1606–1612.PubMedCrossRefGoogle Scholar
  96. 96.
    Leonard JP, Coleman M, Kostakoglu L: Fludarabine monophosphate followed by iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin’s lymphoma (NHL). Blood 1999; 94: 90a (abstr)Google Scholar
  97. 97.
    Kunkel LA: Idiotype vaccines in the treatment of B-cell non-Hodgkin’s lymphoma. Cancer Invest 2004; 22: 97–105PubMedCrossRefGoogle Scholar
  98. 98.
    Kwak LW, Campbell MJ, Czerwinski DK, et al: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1209–1215PubMedCrossRefGoogle Scholar
  99. 99.
    Laport GG, Levine BL, Stadtmauer EA, et al: Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003; 102: 2004–2013PubMedCrossRefGoogle Scholar
  100. 100.
    Horning SJ, Negrin RS, Hoppe RT, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 404–409PubMedCrossRefGoogle Scholar
  101. 101.
    Freedman AS, Gribben JG, Neuberg D, et al High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780–2786PubMedGoogle Scholar
  102. 102.
    Schouten HC, Qian W, Kvaloy-Schouten S, et al: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: Results from the randomized European CUP Trial. J Clin Oncol 2003; 21: 3918–3927PubMedCrossRefGoogle Scholar
  103. 103.
    Lenz G, Dreyling M, Schiegnitz E, et al: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667–2674PubMedCrossRefGoogle Scholar
  104. 104.
    Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–1480PubMedGoogle Scholar
  105. 105.
    Khouri IF, Saliba RM, Giralt SA, et al: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-hosts disease, and treatment-related mortality. Blood 2001; 98: 3595–3599PubMedCrossRefGoogle Scholar
  106. 106.
    Ketterer N, Salles G, Moullet I, et al: Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–242PubMedCrossRefGoogle Scholar
  107. 107.
    Yamauchi T, Nowak BJ, Keating MJ, et al: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Can Res 2001; 7: 580–3589Google Scholar
  108. 108.
    Velasquez WS, McLaughlin P, Tucker S, et al: ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176PubMedGoogle Scholar
  109. 109.
    El Gnaoui T, Dupuis J, Joly B, et al: Rituximab, gemcitabine and oxaliplatin (R-GEMOX): A promising regimen for refractory/relapsed B-cell lymphoma. Blood 2004; 104(Suppl): 681a (abstr)Google Scholar
  110. 110.
    Davis RE, Brown KK, Siebenlist U, et al: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exper Med 2001; 194: 1861–1874CrossRefGoogle Scholar
  111. 111.
    Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol, in pressGoogle Scholar
  112. 112.
    O’Connor O, Wright J, Moskowitz C, et al: A multicenter experience with singe agent bortezomib in non-Hodgkin’s lymphoma reveals marked difference in sub-type sensitivity to proteasome inhibition. Blood 2004; 104(Suppl): 175a (abstr)Google Scholar
  113. 113.
    Link BK, Wang H, Byrd JC: A phase II study of RemitogenT(Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma. Blood 2001; 98: 2540a (abstr)CrossRefGoogle Scholar
  114. 114.
    Leonard JP, Coleman M, Matthews JC: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin’s lymphoma (NHL). Blood 2002; 100: 358a (abstr)Google Scholar
  115. 115.
    Grossbard ML, Lambert JM, Goldmacher VS, et a: Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11: 726–737PubMedGoogle Scholar
  116. 116.
    Vitetta ES, Stone M, Amlot P, et al: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991; 51: 4052–4058PubMedGoogle Scholar
  117. 117.
    Dang NH, Hagemeister FB, Pro B, et al: Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin’s lymphoma: J Clin Oncol 2004; 22: 4095–4102PubMedCrossRefGoogle Scholar
  118. 118.
    DeNardo GL, DeNardo SJ, Goldstein DS, et al: Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol 1998; 16: 3246–3256PubMedGoogle Scholar
  119. 119.
    Kaminiski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 121 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2001; 19: 3918–3928Google Scholar
  120. 120.
    Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20: 2453–2463PubMedCrossRefGoogle Scholar
  121. 121.
    Liu SY, Eary JF, Petersondorf SH, et al: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16: 3270PubMedGoogle Scholar
  122. 122.
    Leonard JP, Coleman M, Matthews JC, et al: Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin’s lymphoma: preliminary response data. Proc ASCO 2002; 21: 266a (abstr)Google Scholar
  123. 123.
    Sacchi S, Federico M, Vitolo U, et al: Clinical activity and safety of combination immunohterapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin’s lymphoma. Haematologica 2001; 86: 951–958PubMedGoogle Scholar
  124. 124.
    Liu NS, Grimm E, Poindexter N: Antibody dependent cellular cytotoxicity and natural killer cell activity in patients with recurrent indolent lymphoma receiving rituximab in combination with GM-CSF. Blood 2003, 102: 411a (abstr)Google Scholar
  125. 125.
    van der Kolk LE, Grillo-López, Baars JW, and van Oers MHJ: Treatment of relapsed B-cell non-Hodgkin’s lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 2003; 17: 1658–1664PubMedCrossRefGoogle Scholar
  126. 126.
    Ansell SM, Witzig TE, Kurtin PJ, et al: Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 2002; 99: 67–74PubMedCrossRefGoogle Scholar
  127. 127.
    Pro B, Smith MR, Younes A, et al: Genasense (Bcl-2 antisense) plus rituximab is active in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Blood 2003; 102, (abstr 1491).Google Scholar
  128. 128.
    Rohatiner AZS, Johnson PWM, Price CGA, et al: Myeloablative therapy with autologous bone marrow transplantation as consolidation for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177–1184PubMedGoogle Scholar
  129. 129.
    Pedersen-Bjergaard J, Pedersen M, Myhre J, et al: High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas in mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia 1997; 11: 1654–1660PubMedCrossRefGoogle Scholar
  130. 130.
    Hosing C, Saliba RM, McLaughlin P, et al: Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patient with refractory or recurrent indolent non-Hodgkin’s lymphoma. Ann Oncol 2003; 14: 737–744PubMedCrossRefGoogle Scholar
  131. 131.
    Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK: Unmutated IgV (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854PubMedGoogle Scholar
  132. 132.
    Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348: 1777–1785PubMedCrossRefGoogle Scholar
  133. 133.
    Rassenti LZ, Huynh L, Toy TL, et al: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901PubMedCrossRefGoogle Scholar
  134. 134.
    Thieblemont C, Nasser V, Felman P, et al: Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 2004; 103: 2727–2737PubMedCrossRefGoogle Scholar
  135. 135.
    Almasri NM, Duque RE, Iturraspe J, et al: Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992; 40: 259–263PubMedCrossRefGoogle Scholar
  136. 136.
    Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21: 1746–1751PubMedCrossRefGoogle Scholar
  137. 137.
    Venugopal P, Sivaraman S, Huang XK, et al: Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000; 24: 411–415PubMedCrossRefGoogle Scholar
  138. 138.
    Keating MJ, Chiorazzi N, Messmer B, et al: Biology and treatment of chronic lymphocytic leukemia. Hematology 2003; 153–175Google Scholar
  139. 139.
    Kay NE, Geyer SM, Lin T, et al: Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia. Blood 2004; 104(Suppl): 100a (abstr)Google Scholar
  140. 140.
    Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campth-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561PubMedCrossRefGoogle Scholar
  141. 141.
    Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus panel recommendations from the Second International Workshlop on Waldenstrom’s Macroglobulinemia. Semin Oncol Oncol 2003; 30: 110–115CrossRefGoogle Scholar
  142. 142.
    Offit K, Parsa NZ, Filippa D, et al: (9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin’s lymphoma with plasmacytoid differentiation. Blood 1992; 80: 2594–2599PubMedGoogle Scholar
  143. 143.
    Zuckerman E, Zuckerman T: Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997; 127: 423–428PubMedGoogle Scholar
  144. 144.
    Pozzato G, Mazzaro C, Crovatto M, et al: Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994; 84: 3047–3053PubMedGoogle Scholar
  145. 145.
    Gertz MA, Anagnostopoulos A, Anderson K, et al: Treatment recommendations in Waldenstrom’s macroglobulinemia consensus panel recommendations in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 2003; 30: 121–126PubMedCrossRefGoogle Scholar
  146. 146.
    Zucca E, Bertoni F, Roggero E, et al: Management of rare forms of lymphoma. Curr Opin Oncol 1998; 10: 377–384PubMedCrossRefGoogle Scholar
  147. 147.
    Nathwani BN, Anderspm KR, Armitage JO, et al: Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. J Clin Oncol 1999; 17: 2486–2492PubMedGoogle Scholar
  148. 148.
    Arcaini L, Paulli M, Boveri E, et al: Marginal zone-related neoplasms of splenic and nodal origin. Haematologica 2003; 88: 80–93PubMedGoogle Scholar
  149. 149.
    Zucca E, Conconi A, Pedrinis E, et al: Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101: 2489–2495PubMedCrossRefGoogle Scholar
  150. 150.
    Berger F, Felman P, Sonet A, et al: Nonfollicular small B-cell lymphomas: a heterogeneous group of patients with distinct clinical features and outcome. Blood 1994; 83: 2829–2835PubMedGoogle Scholar
  151. 151.
    Thieblemont C, de la Fouchardiere A, Coiffier B: Nongastric mucosa-associated lymphoid tissue lymphomas. Clin Lymphoma 2003; 3: 212–224PubMedGoogle Scholar
  152. 152.
    Fisher RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group Study. Blood 1995; 85: 1075–1082PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Peter McLaughlin
    • 1
  1. 1.Department of Lymphoma/MyelomaUniversity of Texas M.D. Anderson Cancer CenterHouston

Personalised recommendations